This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To determine if modafinil can improve fatigue in patients with post-polio syndrome.
Methods: We used a randomized, placebo-controlled crossover trial. Intervention with modafinil (400 mg/day) and placebo occurred over 6-week periods. Primary endpoint (fatigue) was assessed using the Fatigue Severity Scale as the main outcome measure. Other measures included the Visual Analog Scale for Fatigue and the Fatigue Impact Scale. Secondary endpoint (health-related quality of life) was assessed using the 36-Item Short-Form. Analysis of variance for repeated measures was applied to assess treatment, period, and carryover effects.
Results: Thirty-six patients were randomized, 33 of whom (mean age: 61 years) completed required interventions. Treatment with modafinil was safe and well-tolerated. After adjusting for periods and order effects, no difference was observed between treatments.
Conclusion: Based on the utilized measures of outcome modafinil was not superior to placebo in alleviating fatigue or improving quality of life in the studied post-polio syndrome population.
Footnotes
-
Sponsored by the Post-Polio Syndrome Program through a grant from the Department of Defense to the Uniformed Services University of the Health Sciences (Health Affairs, Grant MDA 905-01-007). The PPS Program is administered under the auspices of the Henry Jackson Foundation (HJF, www.hjf.org), Rockville, Maryland. The funding organization had no role in the study design, data collection, data analyses, interpretation of results, or drafting of the final report. The corresponding author had full access to the data and has final responsibility for the information submitted for publication.
Disclaimer: The opinions or assertions contained herein are the private views of the authors and are not to be construed as official, or as reflecting the views of the Department of the Army or the Department of Defense.
Disclosure: The authors report no conflicts of interest.
Presented in part at the annual meeting of the American Academy of Neurology; San Diego, CA; Neurology 2006; P04.201(suppl 2):A248.
Received August 17, 2006. Accepted in final form January 10, 2007.
AAN Members: Sign in with your AAN member credentials (e-mail or 6-digit Member ID number)
Non-AAN Member subscribers: Sign in with subscriber credentials
Log in using your username and password
Purchase access
Disputes & Debates: Rapid online correspondence
- Modafinil for treatment of fatigue in post-polio syndrome: A randomized controlled trial
- Reply from the authors
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.